Robin Shane Readnour is Director at AN2 Therapeutics, Inc. (ANTX). They have made 4 open-market trades across 1 company since 2022, most recently 2026-09-09.
CIK 0001914883
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $2.6M since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANTX | 624,765 | $2.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANTX | SELL · 10b5-1 | 2026-09-09 | 2026-09-11 | $6.02 | $7K | -11.2% | -20.8% | — |
| ANTX | SELL · 10b5-1 | 2026-09-03 | 2026-09-08 | $6.04 | $97K | -16.1% | -22.3% | — |
| ANTX | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $6.01 | $213K | -9.1% | -17.8% | — |
| ANTX | BUY | 2024-12-06 | 2024-12-10 | $1.44 | $79K | -19.7% | -20.4% | -14.0% |
| ANTX | BUY | 2024-11-26 | 2024-11-27 | $1.41 | $53K | +2.0% | -2.7% | -25.0% |
| ANTX | BUY | 2024-11-19 | 2024-11-21 | $1.07 | $213K | +18.3% | +11.1% | -8.7% |
| ANTX | SELL · 10b5-1 | 2024-01-12 | 2024-01-17 | $21.91 | $31K | -3.8% | -82.5% | -88.1% |
| ANTX | SELL · 10b5-1 | 2024-01-10 | 2024-01-12 | $21.93 | $80K | +0.8% | -74.2% | -84.8% |
| ANTX | BUY | 2022-03-29 | 2022-03-31 | $15.00 | $2.3M | -9.0% | +8.9% | -48.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.